CORE
🇺🇦
make metadata, not war
Services
Services overview
Explore all CORE services
Access to raw data
API
Dataset
FastSync
Content discovery
Recommender
Discovery
OAI identifiers
OAI Resolver
Managing content
Dashboard
Bespoke contracts
Consultancy services
Support us
Support us
Membership
Sponsorship
Community governance
Advisory Board
Board of supporters
Research network
About
About us
Our mission
Team
Blog
FAQs
Contact us
Inhibitory effects of the β2-adrenergic receptor agonist zilpaterol on the LPS-induced production of TNF-α in vitro and in vivo
Authors
R.P. Doornbos
J. van der Greef
+3 more
R.J.T. Rodenburg
K.C.M. Verhoeckx
R.F. Witkamp
Publication date
1 January 2005
Publisher
Abstract
In this study the anti-inflammatory properties of zilpaterol, a β2-adrenergic receptor (AR) agonist specifically developed as a growth promoter in cattle were investigated. Although zilpaterol has a different structure compared with the β2-AR agonists known to date, it was noted that it was able to bind to both the β2-AR (K i = 1.1 × 10-6) and the β1-AR (Ki = 1.0 × 10-5). Using lipopolysaccharide (LPS)-exposed U937 macrophages, the production of cyclic adenosine-3′, 5′-cyclic monophosphate (cAMP) and tumor necrosis factor alpha (TNF-α) were investigated. Zilpaterol inhibited TNF-α release and induced intracellular cAMP levels in a dose-dependent manner. The inhibition of TNF-α release and induction of cAMP production was mainly mediated via the β2-AR, as indicated by addition of β1- and β2-specific antagonists. The effects of zilpaterol were investigated in LPS-treated male Wistar rats after pretreatment with zilpaterol. Zilpaterol dosed at 500 μg/kg body weight reduced the TNF-α plasma levels. In conclusion, zilpaterol is a β2-adrenergic agonist and an inhibitor of TNF-α production induced by LPS both in vivo and in vitro. © 2005 Blackwell Publishing Ltd
Similar works
Full text
Available Versions
NARCIS
See this paper in CORE
Go to the repository landing page
Download from data provider
Last time updated on 03/09/2017